CUDC-101
7-((4-((3-ethynylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-N-hydroxyheptanamide
CUDC-101 is a novel hybrid dual-acting HDAC and receptor tyrosine kinase inhibitor. It is a potent HDAC inhibitor which also inhibits EGFR and HER2,IC50 = 4.4, 2.4 and 15.7 nM respectively. It not only blocks EGFR and HER2 but also attenuates multiple compensatory pathways such as AKT, HER3 and MET which enable tumor cells to escape the effects of conventional EGFR/HER2 inhibitors
Physical Properties: White to off-white powder
MW = 434.5 C24H26N4O4
Analysis: >99% (HPLC); NMR (Conforms); MP=188-190oC
Solubilization: May be dissolved in DMSO (25 mg/ml)
Storage: Store desiccated as supplied at -20°C for up to 2 years. Store solutions at-20°C for up to 1 month.
Amount: 5mg
